BTK inhibitors synergise with 5‐FU to treat drug‐resistant TP53 ‐null colon cancers-Reference-Cited by-同舟云学术

BTK inhibitors synergise with 5‐FU to treat drug‐resistant TP53 ‐null colon cancers

Published:2019-12-02 Issue:2 Volume:250 Page:134-147
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Lavitrano Marialuisa¹,Ianzano Leonarda¹,Bonomo Sara¹,Cialdella Annamaria¹,Cerrito Maria Grazia¹,Pisano Fabio¹,Missaglia Carola¹,Giovannoni Roberto¹,Romano Gabriele¹,McLean Chelsea M²,Voest Emile E²,D'Amato Filomena³,Noli Barbara³,Ferri Gian Luca³,Agostini Marco⁴⁵,Pucciarelli Salvatore⁴,Helin Kristian⁶,Leone Biagio E¹,Canzonieri Vincenzo⁷,Grassilli Emanuela¹^ORCID

Affiliation:

1. School of Medicine and Surgery University of Milano‐Bicocca Monza Italy

2. Department of Molecular Oncology and Immunology The Netherlands Cancer Institute Amsterdam The Netherlands

3. NEF‐Laboratory, Department of Biomedical Science University of Cagliari Cagliari Italy

4. First Surgical Clinic Section, Department of Surgery, Oncology and Gastroenterology University of Padova Padova Italy

5. Department of Nanomedicine The Methodist Hospital Research Institute Houston TX USA

6. Center for Epigenetics Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center New York NY USA

7. Pathology Unit and CRO Biobank CRO Aviano National Cancer Institute Aviano Italy

Funder

Ministero dell’Istruzione, dell’Università e della Ricerca

Università degli Studi di Milano-Bicocca

Ministero della Salute

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/path.5347

Reference70 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

3. Corrections to “Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

4. NCCN Guidelines Insights: Colon Cancer, Version 2.2018

5. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sparse spectral graph analysis and its application to gastric cancer drug resistance-specific molecular interplays identification;PLOS ONE;2024-07-05

2. Evaluation of volatile components from the tuber, fibrous roots, bud, stem and leaf tissues of Bletilla striata for its anti-colon cancer activity;Physiology and Molecular Biology of Plants;2024-04

3. BTK Expression Level Prediction and the High-Grade Glioma Prognosis Using Radiomic Machine Learning Models;Journal of Imaging Informatics in Medicine;2024-02-21

4. HZ-A-018, a novel inhibitor of Bruton tyrosine kinase, exerts anti-cancer activity and sensitizes 5-FU in gastric cancer cells;Frontiers in Pharmacology;2023-03-22

5. Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials;Molecules;2023-03-06